A groundbreaking study recently published in Nature Communications has unveiled a novel molecular pathway that worsens liver damage during ischemia-reperfusion injury (IRI), a condition that occurs when the blood supply to the liver is temporarily cut off and then restored. The research, led by Peng, Wang, Lei, and colleagues, reveals that the protein Btg2 inhibits the UFMylation of Fmo1, thereby intensifying both ferroptosis and apoptosis in hepatic cells. This finding opens up new avenues for therapeutic intervention in liver diseases characterized by IRI, positioning UFMylation machinery as a critical regulator of cell death pathways.
Hepatic ischemia-reperfusion injury remains a formidable clinical challenge, particularly in liver surgery and transplantation. The sudden return of blood flow triggers oxidative stress, inflammation, and an array of cell death mechanisms that contribute to extensive tissue damage. Two key processes implicated in this damage are ferroptosis, an iron-dependent lipid peroxidation-driven cell death, and apoptosis, a programmed and regulated form of cell demise. Understanding how molecular regulators modulate these pathways is crucial for designing targeted therapies to protect the liver.
At the core of the study lies the intersection between Btg2 (B-cell translocation gene 2) and Fmo1 (Flavin-containing monooxygenase 1), with UFMylation—a relatively recently discovered ubiquitin-like post-translational modification—as the connecting thread. UFMylation, akin to ubiquitination, modifies specific target proteins to alter their stability, localization, or function, thus influencing cellular processes. Although UFMylation’s biological significance is just being unraveled, it is increasingly recognized as a vital modulator of stress responses and protein homeostasis.
The researchers first identified elevated Btg2 expression in hepatocytes subjected to ischemia-reperfusion conditions in both in vitro cell culture models and in vivo murine models. This upregulation correlated with increased markers of oxidative damage and cell death. Notably, Btg2 overexpression exacerbated cell injury outcomes, prompting the team to investigate whether Btg2 directly influenced cell death pathways or operated through intermediate molecular targets.
Through a combination of co-immunoprecipitation, mass spectrometry, and mutagenesis experiments, the investigators demonstrated that Btg2 physically interacts with Fmo1 and hinders its post-translational modification via UFMylation. Fmo1 is an enzyme traditionally known for catalyzing the oxidation of xenobiotics, but emerging data highlight its roles in regulating cellular redox balance and lipid metabolism, which are crucial in determining cell fate during oxidative stress.
Inhibition of Fmo1 UFMylation by Btg2 led to a functional decline in Fmo1’s capacity to mitigate oxidative damage within hepatocytes. This decline in enzymatic activity created a permissive environment for lipid peroxidation and iron accumulation, hallmark features triggering ferroptosis. At the same time, Btg2’s suppression of UFMylation influenced apoptotic signaling pathways downstream, potentially by affecting mitochondrial integrity and caspase activation.
The study meticulously quantified ferroptotic biomarkers such as increased lipid peroxides and reduced glutathione pools, while also monitoring apoptotic indicators including caspase-3 cleavage and DNA fragmentation. Btg2 overexpression yielded a dramatic enhancement of these markers post-ischemia-reperfusion, linking its role directly to the intensification of cell death modalities. Conversely, genetic knockdown of Btg2 or pharmacologic promotion of Fmo1 UFMylation conferred significant cytoprotection.
Furthermore, in vivo experiments using mouse models recapitulated these findings, with Btg2 genetic ablation resulting in reduced liver enzyme release (AST/ALT), lower histological injury scores, and diminished markers of ferroptosis and apoptosis following hepatic IRI. These functional outcomes affirm Btg2 as a tangible molecular target, providing compelling evidence for therapeutic modulation.
Mechanistically, the research underscores that Btg2 acts as a negative regulator of the UFMylation system, offering the first insight into how post-translational modifications can fine-tune the balance between survival and death in hepatocytes under ischemic stress. The delicate interplay between Btg2 and Fmo1 extends our understanding of how enzymatic activity and protein modifications interlock to decide cellular fate during pathophysiologic insults.
This discovery implicates the UFMylation pathway as a master regulator and highlights its potential as a druggable axis. Targeting Btg2 or augmenting Fmo1 UFMylation could be a transformative strategy to prevent liver injury in clinical settings like transplantation, trauma, and hepatic surgeries. Future pharmacologic explorations focusing on small molecules or biologics to modulate this axis may yield novel hepatoprotective agents.
Moreover, the study sets the stage for broader investigations into how UFMylation interfaces with other liver diseases characterized by oxidative and metabolic stress. Given the liver’s central role in systemic metabolism and detoxification, fine-tuning such post-translational modifications could have ripple effects on multiple organ systems affected by ischemia-reperfusion and inflammatory injuries.
In an era where precision medicine seeks to tailor interventions to molecular profiles, the identification of Btg2-Fmo1 interactions introduces a new biomarker axis. We may soon be able to stratify patients based on the expression or activity of these proteins, adapting perioperative care to mitigate injury risks and improve outcomes.
While therapeutic options for ferroptosis have been limited, this work energizes the field of cell death research by connecting oxidative lipid damage control with protein modification machinery. The dual impact on ferroptosis and apoptosis further amplifies the potential clinical relevance, since combinatorial inhibition of multiple cell death pathways may prove more effective than single-target approaches.
In summary, the work of Peng, Wang, Lei, and colleagues spotlights an intricate regulatory mechanism whereby Btg2 impairs Fmo1’s protective UFMylation, thereby catalyzing irreversible damage in hepatic ischemia-reperfusion injury. This insight opens a promising therapeutic frontier by unveiling how modulation of post-translational modifications can influence lethal cellular processes and improve hepatic viability.
As the field progresses, this study will surely inspire a wave of research dedicated to dissecting UFMylation’s broader biological roles and exploring novel molecular therapies. The convergence of enzymology, cell death biology, and liver pathophysiology embodied in this research charts a new course toward effective treatment strategies for conditions plagued by ischemic insult and oxidative stress.
Subject of Research:
The molecular mechanisms by which Btg2 affects Fmo1 UFMylation and its impact on ferroptosis and apoptosis in hepatic ischemia-reperfusion injury.
Article Title:
Btg2 inhibits Fmo1 UFMylation thus exacerbating ferroptosis and apoptosis in hepatic ischemia-reperfusion injury.
Article References:
Peng, D., Wang, Y., Lei, D. et al. Btg2 inhibits Fmo1 UFMylation thus exacerbating ferroptosis and apoptosis in hepatic ischemia-reperfusion injury. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72455-z
Image Credits: AI Generated
